{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:12:07Z","timestamp":1761624727431,"version":"build-2065373602"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T00:00:00Z","timestamp":1416355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.dld.2014.10.002","type":"journal-article","created":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T12:18:41Z","timestamp":1415276321000},"page":"S197-S205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S5","title":["Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease"],"prefix":"10.1016","volume":"46","author":[{"given":"Sabela","family":"Lens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2014.10.002_bib0005","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.10.002_bib0010","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.10.002_bib0015","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.10.002_bib0020","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.10.002_bib0025","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.10.002_bib0030","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) \u2013 NCT01514890","volume":"59","author":"Hezode","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0035","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0168-8278(13)60067-7","article-title":"Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced disease-predictive factors for sepsis","volume":"58","author":"Rutter","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0040","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.10.002_bib0045","article-title":"Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis","author":"Lawitz","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon Alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2014.10.002_bib0055","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon Alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"issue":"Suppl. 4","key":"10.1016\/j.dld.2014.10.002_bib0060","first-page":"756A","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-na\u00efve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST-1 and 2 phase III trials","volume":"58","author":"Jacobson","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0065","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.10.002_bib0070","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial","volume":"146","author":"Zeuzem","year":"2014","journal-title":"Gastroenterology"},{"year":"2014","series-title":"24th conference of the Asian Pacific Association for the Study of the Liver (APASL)","author":"Reddy","key":"10.1016\/j.dld.2014.10.002_bib0075"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0080","first-page":"553A","article-title":"Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon Alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results","volume":"56","author":"Hezode","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0085","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1016\/S0168-8278(13)61417-8","article-title":"Daclatasvir combined with peginterferon Alfa 2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2\/3 study","volume":"58","author":"Dore","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0090","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2013.109309","article-title":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial","volume":"310","author":"Osinusi","year":"2013","journal-title":"Journal of the American Medical Association"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0095","first-page":"S523","article-title":"Simeprevir plus Sofosbuvir with\/without ribavirin in HCV genotype 1 prior null-responder\/treatment-naive patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3\u20134 (COHORT 2)","volume":"60","author":"Lawitz","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.10.002_bib0105","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.10.002_bib0110","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.10.002_bib0115","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0120","doi-asserted-by":"crossref","first-page":"S524","DOI":"10.1016\/S0168-8278(14)61461-6","article-title":"All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: phase 3 study results","volume":"60","author":"Manns","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0125","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0168-8278(14)60063-5","article-title":"Efficacy and safety of MK-5172 and MK-8742\u00b1ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: the C-WORTHY Study","volume":"60","author":"Lawitz","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0130","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.10.002_bib0135","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2014.10.002_bib0140","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.10.002_bib0440","unstructured":"Pawlotsky JM, Aghemo A, Dusheiko G, et al. EASL recommendation on treatment of hepatitis C 2014; http:\/\/files.easl.eu\/easl-recommendations-on-treatment-of-hepatitis-C\/index.html (accessed October 2014)."},{"key":"10.1016\/j.dld.2014.10.002_bib0150","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2004.01.005","article-title":"Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients","volume":"40","author":"Planas","year":"2004","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0155","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/apt.12721","article-title":"Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients","volume":"39","author":"D\u2019Amico","year":"2014","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2014.10.002_bib0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2014.03.012","article-title":"Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C","volume":"107","author":"Lee","year":"2014","journal-title":"Antiviral Research"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0165","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0168-8278(14)60070-2","article-title":"Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety","volume":"60","author":"Afdhal","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.dld.2014.10.002_bib0170","first-page":"S398","article-title":"The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days","volume":"56","author":"Lawitz","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 4","key":"10.1016\/j.dld.2014.10.002_bib0175","first-page":"555A","article-title":"Pharmacokinetics and safety of co-administered ABT-450 plus ritonavir (ABT 450\/r), ABT-267 and ABT-333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate and severe hepatic impairment","volume":"56","author":"Khatri","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0180","first-page":"1065A","article-title":"Effect of hepatic impairment on the pharmacokinetics of asunaprevir (BMS-650032, ASV)","volume":"56","author":"Eley","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0185","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1016\/S0168-8278(13)60889-2","article-title":"Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment. Abstract","volume":"58","author":"Ouwerkerk-Mahadevan","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0190","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.lts.2003.09.018","article-title":"Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry","volume":"9","author":"Adam","year":"2003","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2014.10.002_bib0195","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","article-title":"Hepatitis C virus kinetics during and immediately after liver transplantation","volume":"35","author":"Garcia-Retortillo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0200","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/lt.21093","article-title":"Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study","volume":"13","author":"Belli","year":"2007","journal-title":"Liver Transplantation"},{"issue":"Pt 1","key":"10.1016\/j.dld.2014.10.002_bib0205","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1053\/jhep.2000.17924","article-title":"Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation","volume":"32","author":"Berenguer","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0210","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/lt.21117","article-title":"A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation","volume":"13","author":"Yilmaz","year":"2007","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2014.10.002_bib0215","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/lt.21000","article-title":"Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center","volume":"13","author":"Walter","year":"2007","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2014.10.002_bib0220","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jhep.2004.06.029","article-title":"Fibrosis progression after liver transplantation in patients with recurrent hepatitis C","volume":"41","author":"Neumann","year":"2004","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0225","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jhep.2012.12.014","article-title":"Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment","volume":"58","author":"Berenguer","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0230","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.10.002_bib0235","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.02.011","article-title":"Viral hepatitis in liver transplantation","volume":"142","author":"Crespo","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.10.002_bib0240","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2008.11.015","article-title":"Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study","volume":"50","author":"Carrion","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0245","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0168-8278(03)00310-6","article-title":"Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation","volume":"39","author":"Forns","year":"2003","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0250","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/hep.25976","article-title":"A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation","volume":"57","author":"Everson","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0255","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hep.20793","article-title":"Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy","volume":"42","author":"Everson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0260","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1600-6143.2011.03491.x","article-title":"Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation","volume":"11","author":"Coto-Llerena","year":"2011","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.dld.2014.10.002_bib0265","article-title":"High post-transplant virologic response in hepatitis C virus infected patients treated with pre-transplant protease inhibitor-based triple therapy","author":"Verna","year":"2014","journal-title":"Liver International"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0270","first-page":"314A","article-title":"Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation","volume":"58","author":"Curry","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0275","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1053\/j.gastro.2008.07.072","article-title":"Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon\/ribavirin therapy","volume":"135","author":"Ferenci","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.10.002_bib0280","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jhep.2010.02.002","article-title":"Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy","volume":"52","author":"Neumann","year":"2010","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0285","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jhep.2010.09.009","article-title":"Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C","volume":"54","author":"Beinhardt","year":"2011","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0290","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy","volume":"57","author":"Peng","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0295","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2009.07.047","article-title":"Trends in waiting list registration for liver transplantation for viral hepatitis in the United States","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.10.002_bib0300","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","article-title":"Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C","volume":"59","author":"Poynard","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0305","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.dld.2014.10.002_bib0310","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/lt.21646","article-title":"The natural history of recurrent hepatitis C and what influences this","volume":"14","author":"Gane","year":"2008","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2014.10.002_bib0315","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.21090","article-title":"Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation","volume":"43","author":"Blasco","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0320","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/lt.20857","article-title":"Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation","volume":"12","author":"Carrion","year":"2006","journal-title":"Liver Transplantation"},{"key":"10.1016\/j.dld.2014.10.002_bib0325","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation","volume":"8","author":"Berenguer","year":"2008","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.dld.2014.10.002_bib0330","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study","volume":"132","author":"Carrion","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2014.10.002_bib0335","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1600-6143.2006.01362.x","article-title":"Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis","volume":"6","author":"Wang","year":"2006","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.dld.2014.10.002_bib0340","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2893.2008.01019.x","article-title":"Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies","volume":"15","author":"Xirouchakis","year":"2008","journal-title":"Journal of Viral Hepatitis"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0345","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/liv.12062","article-title":"Current management and perspectives for HCV recurrence after liver transplantation","volume":"33","author":"Coilly","year":"2013","journal-title":"Liver International"},{"key":"10.1016\/j.dld.2014.10.002_bib0350","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.20560","article-title":"Peginterferon Alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials","volume":"41","author":"Chalasani","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0355","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/gast.2003.50095","article-title":"Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study","volume":"124","author":"Samuel","year":"2003","journal-title":"Gastroenterology"},{"issue":"Suppl. 4","key":"10.1016\/j.dld.2014.10.002_bib0360","first-page":"238A","article-title":"Protease inhibitor-based triple therapy is highly effective in liver transplant recipients with genotype 1 hepatitis C recurrence: a Canadian multicentre experience","volume":"58","author":"Faisal","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0365","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2013.08.018","article-title":"Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience","volume":"60","author":"Coilly","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0370","first-page":"209A","article-title":"Twice daily telaprevir in combination with Peginterferon Alfa 2a\/Ribavirin in genotype 1 HCV liver transplant recipients: interim week 16 safety and efficacy results of HTE prospective multicentre REFRESH study. Abstract","volume":"58","author":"Brown","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2014.04.037","article-title":"A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy","author":"Burton","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0380","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/hep.25831","article-title":"Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers","volume":"56","author":"Hulskotte","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0385","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1128\/AAC.01151-12","article-title":"Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence","volume":"56","author":"Coilly","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.dld.2014.10.002_bib0395","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus","volume":"54","author":"Garg","year":"2011","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0400","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0168-8278(14)60116-1","article-title":"Results of the phase 2 study M12-999: interferon-free regimen of ABT-450\/r\/ABT-267+ABT-333+ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection","volume":"60","author":"Kwo","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0405","first-page":"1063A","article-title":"No clinically significant pharmacokinetic drug\u2013drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine a or tacrolimus in healthy volunteers","volume":"56","author":"Mathias","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0410","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/lt.23482","article-title":"Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation","volume":"18","author":"Fontana","year":"2012","journal-title":"Liver Transplantation"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0415","first-page":"S481","article-title":"Interim SVR12 results from the Telaprevir phase3B REPLACE study in treatment-naive stable liver transplant patients with genotype 1 HCV infection","volume":"60","author":"Forns","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0420","doi-asserted-by":"crossref","first-page":"S499","DOI":"10.1016\/S0168-8278(14)61392-1","article-title":"Sofosbuvir and ribavirin for the treatment of recurrent hepatitis C infection after liver transplantation: results of a prospective, multicenter study","volume":"60","author":"Samuel","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0425","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(14)60064-7","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation","volume":"60","author":"Forns","year":"2014","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2014.10.002_bib0430","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.dld.2014.06.004","article-title":"Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late","volume":"46","author":"Pellicelli","year":"2014","journal-title":"Digestive and Liver Disease"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2014.10.002_bib0435","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.1016\/S0168-8278(12)61113-1","article-title":"The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977","volume":"56","author":"Cornpropst","year":"2012","journal-title":"Journal of Hepatology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865814007257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865814007257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:08:43Z","timestamp":1761624523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865814007257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":86,"alternative-id":["S1590865814007257"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2014.10.002","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2014.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}